Acasti Pharma (ACST) said Friday it will change its corporate name to Grace Therapeutics and begin trading on Nasdaq under its new ticker, "GRCE" on Oct. 28.
The name change reflects the company's origin and brand equity from Grace Therapeutics, which developed GTx-104 before merging with Acasti in 2021.
Acasti said it expects to release trial data for GTx-104, an injectable formulation targeting aneurysmal subarachnoid hemorrhage, in early 2025 aiming to submit a new drug application to the US Food and Drug Administration in H1 2025.
The company also said it has re-domiciled to the US as a Delaware corporation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments